Private Equity 24 Hours

Last updated: June 15, 2026, 8:30 PM ET

AI‑Focused Private Credit Surge

Closed $35bn private‑credit pact between Apollo and Blackstone will bankroll Anthropic’s next‑generation AI chips, underscoring private equity’s deepening appetite for generative‑AI infrastructure. The syndicate, the largest credit commitment of the year, allocates roughly half to senior secured loans and the remainder to high‑yield mezzanine tranches, positioning lenders to capture steep spreads as chip demand accelerates. At the same time, Blue Owl led a €355m credit vehicle for Veld Capital, providing follow‑on capital to a pipeline of late‑stage tech deals, a move that mirrors the broader shift toward non‑bank financing for AI‑driven enterprises.

Strategic Exits and Portfolio Realignments

Morgan Stanley consummated a $1.6bn sale of its Brazos Delaware II stake, achieving an 8x EBITDA multiple based on projected 2027 earnings and illustrating the premium investors place on high‑growth private‑equity assets. A few weeks later, H.I.G. Capital divested CRO Celerion for $1.8bn, delivering a sizable cash return to its limited partners and reflecting heightened demand for contract‑research capabilities amid a wave of biotech IPOs. Complementing these exits, Aurelius completed the sale of SEG Electronics to Arteche Group, exiting a niche protection‑relay business that serves over 300 customers in 50 countries, thereby freeing capital for larger‑scale opportunities.

Large‑Scale Take‑Privates and Continuation Funding

Nuvei’s $2.75bn acquisition of Payoneer marks one of the biggest take‑private transactions this quarter, expanding the New‑York‑based payments firm’s global footprint and providing an exit for Advent’s growth‑stage investors. Parallel to the buyout wave, Abry Partners closed a $780m continuation fund for Centauri Health Solutions, allowing the firm to retain a top‑performing healthcare asset while offering existing investors liquidity options. Early in the week, Prime Radiant committed $50m to Cellares, its inaugural growth‑equity investment, signaling confidence in the company’s cell‑therapy manufacturing platform and adding a new healthcare play to the firm’s nascent advisory portfolio.

Portfolio Enhancements and Capital Recycling

L Catterton entered exclusive talks to take a stake in Hyrox, the fast‑growing extreme‑fitness brand, aiming to leverage the firm’s consumer‑sector expertise to accelerate international expansion. In Europe, Elliott built a near‑5% position in Bunzl and is urging the distributor to initiate sizeable buybacks and consider a break‑up review, a strategy that could unlock value for shareholders amid margin pressure. Meanwhile, Birkenstock prepared a €900m bond issuance to fund share‑repurchases, marking the German footwear maker’s first bond sale in over five years and reflecting a broader trend of private‑equity‑backed companies turning to debt markets for shareholder returns. Finally, Sycamore Partners lost a suitor as Sigma Healthcare withdrew from the Boots sale, highlighting the challenges of divesting legacy retail assets in a market where strategic fit and regulatory scrutiny increasingly dictate deal outcomes.